Rozlytrek is indicated for treating NTRK fusion-positive solid tumours and
ROS1-positive advanced or metastatic non-small cell lung cancer.1,2
Click here to access Rozlytrek patient materials
Click here to email your local Conditions Partner for more information
Click here to access the dosage information page
References:
- https://www.nice.org.uk/guidance/TA644 last accessed August 2020
- https://www.nice.org.uk/guidance/ta643 last accessed August 2020
- ROZLYTREK Summary of Product Characteristics available at: www.medicines.org.uk/emc
Abbreviations
NTRK: neurotrophic tyrosine receptor kinase
NSCLC: non-small cell lung cancer
Reporting Adverse Events
▼ ROZLYTREK is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
M-GB-00002179
November 2020